PDF(Pubmed)
Abstract：
UNASSIGNED: The five-year recurrence rate of hepatocellular carcinoma (HCC) remains as high as 70%. A complete clinical response has not been observed without surgical resection. Here, we report a rare case of clinical complete response and long-term survival in a patient with massive HCC receiving treatment with immunotherapy, anti-angiogenic therapy, and radiotherapy.
UNASSIGNED: A 38-year-old woman presented to our hospital for abdominal pain that persisted for 3 months. She was diagnosed as Barcelona Clinic Liver Cancer(BCLC) stage A, with a Cancer of the Liver Italian Program (CLIP) score of 3, American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) staging systems stage IB. She refused surgical resection and trans-arterial chemoembolization and accepted a non-invasive systematic treatment strategy involving immunotherapy, anti-angiogenic therapy, and radiotherapy. Her tumor burden decreased, and she experienced partial response before radiotherapy. Following radiotherapy, she experienced a complete clinical response and has been alive for more than 36 months after her initial presentation. She is currently alive.
UNASSIGNED: A non-invasive systematic treatment strategy is a potential radical treatment option for patients with massive HCC.
UNASSIGNED: A 38-year-old woman presented to our hospital for abdominal pain that persisted for 3 months. She was diagnosed as Barcelona Clinic Liver Cancer(BCLC) stage A, with a Cancer of the Liver Italian Program (CLIP) score of 3, American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) staging systems stage IB. She refused surgical resection and trans-arterial chemoembolization and accepted a non-invasive systematic treatment strategy involving immunotherapy, anti-angiogenic therapy, and radiotherapy. Her tumor burden decreased, and she experienced partial response before radiotherapy. Following radiotherapy, she experienced a complete clinical response and has been alive for more than 36 months after her initial presentation. She is currently alive.
UNASSIGNED: A non-invasive systematic treatment strategy is a potential radical treatment option for patients with massive HCC.
摘要：
■肝细胞癌（HCC）的五年复发率仍高达70％。没有手术切除没有观察到完全的临床反应。这里,我们报告了一例罕见的临床完全缓解和长期生存的大规模肝癌患者接受免疫治疗治疗，抗血管生成治疗,和放射治疗。
■一名38岁的妇女因腹痛持续3个月来我院就诊。她被诊断为巴塞罗那诊所肝癌（BCLC）A期，意大利肝癌项目（CLIP）得分为3分，美国癌症联合委员会（AJCC）肿瘤淋巴结转移（TNM）分期系统IB期。她拒绝手术切除和经动脉化疗栓塞，并接受了包括免疫治疗的非侵入性系统治疗策略。抗血管生成治疗,和放射治疗。她的肿瘤负担减轻了,放疗前她有部分反应.放疗后，她经历了完全的临床反应，并且在初次就诊后已经存活了36个月以上。她目前还活着。
■非侵入性系统治疗策略是巨大HCC患者的潜在根治性治疗选择。
■一名38岁的妇女因腹痛持续3个月来我院就诊。她被诊断为巴塞罗那诊所肝癌（BCLC）A期，意大利肝癌项目（CLIP）得分为3分，美国癌症联合委员会（AJCC）肿瘤淋巴结转移（TNM）分期系统IB期。她拒绝手术切除和经动脉化疗栓塞，并接受了包括免疫治疗的非侵入性系统治疗策略。抗血管生成治疗,和放射治疗。她的肿瘤负担减轻了,放疗前她有部分反应.放疗后，她经历了完全的临床反应，并且在初次就诊后已经存活了36个月以上。她目前还活着。
■非侵入性系统治疗策略是巨大HCC患者的潜在根治性治疗选择。
